Graybug Vision (GRAY) Stock Price, News & Analysis

Company Overview

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

Key Stats

• Today's Range: $2.76 to $2.89
• 50-Day Range: $2.70 to $4.80
• 52-Week Range: $5.00 to $22.12
• Volume: 68,617 shs
• Average Volume: 2,165 shs
• Market Capitalization: $4.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GRAY Stock Analysis - Frequently Asked Questions

How have GRAY shares performed this year?

Graybug Vision's stock was trading at $2.86 on January 1st, 2024. Since then, GRAY shares have decreased by 3.5% and is now trading at $2.76.
View the best growth stocks for 2024 here.

How were Graybug Vision's earnings last quarter?

Graybug Vision, Inc. (NASDAQ:GRAY) announced its quarterly earnings results on Thursday, November, 11th. The company reported ($5.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.18) by $0.14.

When did Graybug Vision's stock split?

Shares of Graybug Vision reverse split before market open on Monday, March 20th 2023. The 1-14 reverse split was announced on Monday, March 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Graybug Vision IPO?

Graybug Vision (GRAY) raised $75 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Needham & Co. and Wedbush PacGrow were co-managers.

How do I buy shares of Graybug Vision?

Shares of GRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Graybug Vision own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Graybug Vision investors own include Tesla (TSLA), Plug Power (PLUG), Athenex (ATNX), NIO (NIO), Moderna (MRNA), Pinterest (PINS).

Company Calendar

• Last Earnings: 11/11/2021
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GRAY
• CUSIP: N/A
• CIK: 1534133
• Web: www.graybug.com
• Phone: N/A
• Fax: N/A
• Employees: 27
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($24.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,600,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -77.61%
• Return on Assets: -71.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.73
• Quick Ratio: 10.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 1,571,000
• Free Float: 20,250,000
• Market Cap: $4.34 million
• Optionable: Not Optionable
• Beta: 1.20